fashion -WSS

fashion

author：fashion 2025-09-30 23:00:34 - browse：2

Yichuan Cao/Sipa USA via AP Images

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed.

The result, from a closely watched study called Evoke-01, will be seen as a disappointment by investors and oncologists alike.

Drugs like Trodelvy, known as antibody drug conjugates, are one of the hottest areas in oncology. The idea is that these medicines combine an antibody, which is triggered when it binds to a protein on a cancer cell, with a “payload” of chemotherapy that poisons the cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Morphosys mixed study results for blood cancer drug

WSS

CRISPR pioneers react to Casgevy, first gene

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Montana youths win climate lawsuit against state for promoting fossil fuels

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Aspartame and sugar

In key trial, Verve's treatment lowers cholesterol levels in patients

hotspot

fashion

Wikipedia

How to save PrEP access — and even expand it

Health AI: on the border between health care and tech

New air purifier tech could be key to improving indoor air quality

Surge in Apellis stock fueled by confidence in safety of its eye drug

Moonlake's readout produced a cash windfall. Risks remain

Astellas still sees hope in its gene therapy after four deaths

Jerome Adams on the need for new antivirals for Covid

World's first CRISPR

Hepatitis C has a cure — but many Americans still lack access to it

Treatments for cramps don't cut it. Why aren't there better options?

explore

Weight loss drug costs may need more research, senator suggests

CRISPR pioneers react to Casgevy, first gene

Novo Nordisk touts Wegovy study, but still struggling with supply

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Childhood cancer progress stalls for Black, Hispanic kids: Report

Illumina slashes 2023 revenue projections yet again

knowledge

focus

hotspot

Wikipedia